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Abstract
Background: The positive antimicrobial effects of increasing concentrations of thiocyanate (SCN-
) and H2O2 on the human peroxidase defence system are well known. However, little is known
about the quantitative efficacy of the human peroxidase thiocyanate H2O2 system regarding
Streptococcus mutans and sanguinis, as well as Candida albicans. The aim of this study was to
evaluate the effect of the enzyme lactoperoxidase on the bactericidal and fungicidal effectiveness of
a thiocyanate-H2O2 combination above the physiological saliva level. To evaluate the optimal
effectiveness curve, the exposure times were restricted to 1, 3, 5, and 15 min.
Results: The bactericidal and fungicidal effects of lactoperoxidase on Streptococcus mutans and
sanguinis and Candida albicans were evaluated by using two test mixtures of a 2.0% (w/v; 0.34 M)
thiocyanate and 0.4% (w/v; 0.12 M) hydrogen peroxide solution, one without and one with
lactoperoxidase. Following the quantitative suspension tests (EN 1040 and EN 1275), the growth
of surviving bacteria and fungi in a nutrient broth was measured. The reduction factor in the
suspension test without lactoperoxidase enzyme was < 1 for all three tested organisms. Thus, the
mixtures of 2.0% (w/v; 0.34 M) thiocyanate and 0.4% (w/v; 0.12 M) hydrogen peroxide had no in
vitro antimicrobial effect on Streptococcus mutans and sanguinis or Candida albicans. However, the
suspension test with lactoperoxidase showed a high bactericidal and fungicidal effectiveness in vitro.
Conclusion: The tested thiocyanate and H2O2 mixtures showed no relevant antimicrobial effect.
However, by adding lactoperoxidase enzyme, the mixtures became not only an effective
bactericidal (Streptococcus mutans and sanguinis) but also a fungicidal (Candida albicans) agent.
Background
Maintaining daily oral hygiene is essential to prevent car-
ies, gingivitis, and periodontitis [1-3]. To support
mechanical plaque control, which is mostly insufficient
[4-6], antiseptics are used in toothpastes and mouth rinses
[7-10].
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septics are limited to avoid side effects, such as discolora-
tion of teeth and tongue, taste alterations, mutations
[11,12], and, for microbiostatic active agents, the risk of
developing resistance or cross-resistance against antibiot-
ics [13]. Therefore, it would seem better to stimulate or
support the innate host defence system, such as the oral
peroxidase-thiocyanate-hydrogen peroxide system.
Human saliva contains peroxidase enzymes and lys-
ozyme, among other innate host defence systems. The
complete peroxidase system in saliva comprises three
components: the peroxidase enzymes (glycoprotein
enzyme), salivary peroxidase (SPO) from major salivary
glands and myeloperoxidase (MPO) from polymorpho-
nuclear leucocytes filtering into saliva from gingival crev-
icular fluid; hydrogen peroxide (H2O2); and an oxidizable
substrate such as the pseudohalide thiocyanate (SCN-)
from physiological sources [14,15]. SPO is almost identi-
cal to the milk enzyme lactoperoxidase (LPO) [16,17]. All
these peroxidase enzymes catalyze the oxidation of the
salivary thiocyanate ion (SCN-) by hydrogen peroxide
(H2O2) to OSCN- and the corresponding acid hypothiocy-
anous acid (HOSCN), O2SCN-, and possibly O3SCN- [18],
which have been shown to inhibit bacterial [19-23], fun-
gal [24], and viral viability [25]. However, the system is
effective only if its components are sufficiently available
in saliva. Salivary concentration of SCN- varies considera-
bly and depends, for instance, on diet and smoking hab-
its. The normal range of salivary SCN- for nonsmokers is
from 0.5 to 2 mM (29–116 mg/l), but in smokers [26,27],
the level can be as high as 6 mM (348 mg/l). Pruitt et al.
[28], for example, see the main limiting component for
the production of the oxidation products of SCN- in whole
saliva to be the hydrogen peroxide (H2O2) concentration.
Thomas et al. [29] showed that the combination of LPO,
SCN-, and 0.3 mM (10.2 mg/l) H2O2 caused complete
inhibition that lasted for nearly 16 h, whereas 0.3 mM
(10.2 mg/l) H2O2 alone had no effect. However, if no
more H2O2 was added, the concentration of the inhibitor
OSCN- fell because of slow decomposition of OSCN-, and,
when OSCN- fell below 0.01 mM (0.74 mg/l), the bacteria
resumed metabolism and growth. The loss of OSCN- over
time is based on decomposition, not on the reaction with
bacteria [29].
The typical concentration of peroxidases in whole saliva is
roughly 5 μg/ml, whereas the MPO concentration (3.6 μg/
ml) is approximately twice the amount of SPO (1.9 μg/
ml) [30]. Therefore, even if SPO is deficient, MPO activity
would probably be adequate for SCN- oxidation in mixed
saliva [30]. The study by Adolphe et al. [31] showed that
the lactoperoxidase system's antimicrobial efficiency can
be enhanced by better concentration ratios of the LPO sys-
tem components. However, this finding was postulated
for only near physiological conditions and did not con-
sider a concentration of thiocyanate and H2O2 higher
than the physiological one.
Rosin et al. [32] showed that, in the saliva peroxidase sys-
tem, increasing SCN-/H2O2 above its physiologic saliva
level reduced plaque and gingivitis significantly compared
to baseline values and a placebo. A new dentifrice formu-
lated on these results showed the same effects regarding
plaque and gingivitis prevention in comparison to a
benchmark product containing triclosan [33]. However,
the effects were not sufficient to recommend using the
SPO system to effectively prevent oral diseases in the long
run.
Thus, the question arose, Is it possible to increase antimi-
crobial effectiveness by adding not just thiocyanate and
hydrogen peroxide but also LPO to oxidize as much the
SCN- anions as possible to become an effective antimicro-
bial agent? Therefore, we conducted a standardized quan-
titative suspension test at a fixed concentration level of all
three components above the physiological one to evaluate
the influence of LPO on the lactoperoxidase-thiocyanate-
hydrogen peroxide system relative to its bactericidal and
fungicidal effectiveness against Streptococcus mutans and
sanguinis and Candida albicans.
Results
The reduction factors (RF) of the test suspensions without
and with LPO on the viability of Streptococcus mutans,
Streptococcus sanguinis, and Candida albicans at differ-
ent time points (1, 3, 5, and 15 min) are shown in tables
1, 2 &3.
The accompanying suspension tests with single compo-
nents (SCN-, LPO) and combinations of two components
(LPO+SCN-, LPO+H2O2) showed no clinically relevant
effects (RF ≤ 0.3) at all time points. Only the single com-
ponent H2O2 showed a reduction factor of 1.5 after 15
min.
Streptococcus mutans
The antibacterial reductions of the thiocyanate-hydrogen
peroxide system without LPO increased with time and
were statistically significantly different between 5 and 15
min. However, they remained at a very low level (RF < 1).
Thus, the suspension without LPO had practically no bac-
tericidal effectiveness. The suspension with LPO showed a
distinct antibacterial reduction (RF 7.49) after 5 min,
which means the complete killing of all cells. Thus, a fur-
ther increase of the reduction factor was not possible. The
comparison between groups A (without LPO) and B (with
LPO) showed a statistically significant difference in favour
of group B after 5 and 15 min (Table 1).Page 2 of 8
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The antibacterial reductions of the thiocyanate-hydrogen
peroxide system without LPO increased with time but
only to a very low level (RF ≤ 1) with practically no bacte-
ricidal effectiveness. The suspension with LPO showed an
effective antibacterial reduction after 5 min (RF 4.01 ±
3.88) and after 15 min (RF 8.12 ± 0.22). The RFs between
3 and 5 min were statistically significantly different. The
comparison between groups A and B showed a statistically
significant difference in favour of B (with LPO) after 15
min (Table 2).
Candida albicans
The antifungal reduction of the thiocyanate-hydrogen
peroxide system without LPO (Group A) increased with
time but only to a very low level (RF < 1) with practically
no fungicidal effectiveness. The suspension with LPO
(Group B) showed an effective fungicidal reduction after
3 min (RF 6.78 ± 0.25), which means the complete killing
of all microbes. Thus, a further increase of the reduction
factor was not possible.
Table 1: Reduction factors of the test thiocyanate hydrogen peroxide microbial suspension without and with LPO to Streptococcus 
mutans at different time points.
Group A Group B A vs. B2
Without LPO With LPO
Time Reduction factor Comparisons within A1 Reduction Factor Comparisons within B1
1 vs. 3 3 vs. 5 5 vs. 15 1 vs. 3 3 vs. 5 5 vs. 15
[min] Mean ± SD p p p Mean ± SD p p p p
1 0.23 ± 0.26 0.03 ± 0.17 0.128
0.844 0.016
3 0.21 ± 0.36 0.53 ± 0.22 0.026
0.375 0.016
5 0.25 ± 0.12 7.49 ± 0.643 < 0.001
0.016 0.375
15 0.69 ± 0.43 7.41 ± 0.693 < 0.001
1) Wilcoxon test with a significant level of < 0.05
2) Mann-Whitney U test with a significance level of < 0.001
3) Complete killing of all cells in test suspension
Table 2: Reduction factors of the test thiocyanate hydrogen peroxide microbial suspension without and with LPO to Streptococcus 
sanguinis at different time points.
Group A Group B A vs. B2
Without LPO With LPO
Time Reduction factor Comparisons within A1 Reduction Factor Comparisons within B1
1 vs. 3 3 vs. 5 5 vs. 15 1 vs. 3 3 vs. 5 5 vs. 15
[min] Mean ± SD p p p Mean ± SD p p p p
1 0.10 ± 0.90 0.13 ± 0.12 0.710
0.609 0.078
3 0.16 ± 0.15 0.78 ± 0.67 0.073
0.109 0.016
5 0.27 ± 0.17 4.01 ± 3.88 0.073
0.016 0.063
15 1.03 ± 0.60 8.12 ± 0.223 < 0.001
1) Wilcoxon test with a significant level of < 0.05
2) Mann-Whitney U test with a significance level of < 0.001
3) Complete killing of all cells in test suspensionPage 3 of 8
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cantly different. The comparison between groups A and B
showed a statistically significant difference in favour of B
(with LPO) after 3 min (Table 3).
Discussion
The applied quantitative suspension tests are recognized
European norm tests for evaluating bactericidal (EN
1040) and fungicidal efficacy (EN 1275) of a newly devel-
oped antiseptic [34,35]. In contrast to common antimi-
crobial tests (inhibition tests), these quantitative
suspension tests facilitate, for example, the strict distinc-
tions between bacteriostatic/fungistatic and bacteriocidal/
fungicidal effects by neutralizing the active agent. The tests
are also useful for determining a quantitative curve for
concentration and time of an antiseptic. Thus, the tests are
suitable for evaluating the effect of LPO on the lactoperox-
idase-thiocyanate-hydrogen peroxide system's antimicro-
bial effects. However, the results must be interpreted
within the limitations of an in vitro test.
The industrially produced LPO enzyme such as that used
in toothpaste [36] was used because of its reproducible
quality. Human SPO is slightly different from industrially
produced LPO. However, the main characteristics of the
industrially produced LPO are identical to saliva peroxi-
dase [16,17]. Based on this similarity, industrially pro-
duced LPO is used instead of SPO in studies and is often
referred to as LPO in the literature [37].
The efficiency of the LPO system depends – besides the
concentration of its components – on exposure time and
pH value [29,31]. Therefore, to determine when the LPO
system or the oxidation products reached their initial opti-
mal bactericidal and fungicidal effectiveness, tests were
conducted at the exposure times of 1, 3, 5, and 15 min.
All tests were conducted at the pKa (pH 5.3) of HOSCN/
OSCN- [38], because pretests showed that the lactoperox-
idase-thiocyanate-hydrogen peroxide system was effective
at 5.3 pH. Lumikari et al. [23] found the optimum pH to
be about 5.0. Increasing the HOSCN/OSCN- concentra-
tion by adding H2O2 could raise the inhibition of Strepto-
coccus mutans in human saliva [21,36] but only at a pH
around 5 and not at neutral pH because of the shift of
OSCN- to HOSCN by a low pH value in favour of HOSCN.
Unlike OSCN-, HOSCN has no charge, which facilitates
penetration through the lipophilic bacterial cell mem-
brane and raises the antimicrobial effectiveness of the
saliva antiperoxidase system [18]. Thus, the most effective
product of the LPO system works around the pH, where
the biofilm/saliva pH level is pathologically effective.
To completely ensure that the tested effect of the lactoper-
oxidase enzyme on the thiocyanate-hydrogen peroxide
system above the physiological concentration level was
not based primarily on single components (H2O2, SCN-,
LPO) or on combination of two components (LPO+SCN-
, LPO+H2O2), accompanying suspension tests were con-
ducted.
With one exception, all accompanying single component
tests showed no clinically relevant antimicrobacterial
effectiveness (RF: ≤ 0.3). Only the single component
H2O2 showed a moderate reduction factor of 1.5 after 15
min. This result is in line with the known bactericidal
effect of H2O2 [29]. However, in combination with LPO,
the effect of H2O2 was reduced compared to its single
Table 3: Reduction factors of the test thiocyanate hydrogen peroxide suspension without and with LPO to Candida albicans at 
different time points.
Group A Group B A vs. B2
Without LPO With LPO
Time Reduction factor Comparisons within A1 Reduction Factor Comparisons within B1
1 vs. 3 3 vs. 5 5 vs. 15 1 vs. 3 3 vs. 5 5 vs. 15
[min] Mean ± SD p p p Mean ± SD p p p p
1 0.12 ± 0.19 0.43 ± 0.33 0.077
0.496 0.004
3 0.26 ± 0.26 6.78 ± 0.253 < 0.001
0.141 0.551
5 0.15 ± 0.13 6.75 ± 0.223 < 0.001
0.004 1.000
15 0.93 ± 0.58 6.74 ± 0.263 < 0.001
1) Wilcoxon test with a significant level of < 0.05
2) Mann-Whitney U test with a significance level of < 0.001
3) Complete killing of all cells in test suspensionPage 4 of 8
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the reaction of LPO with H2O2 [39], are short-lived inter-
mediates that cannot react bactericidally under the test
conditions.
All suspension tests without LPO at all time points
showed no or no clinically relevant antimicrobial effec-
tiveness (highest RF: Streptococcus mutans 0.6, Strepto-
coccus sanguinis 1.0, and Candida albicans 0.9). The low
reduction potential could be based on H2O2 itself or, to a
small extent, on the oxidation without enzyme of SCN- to
OSCN- by H2O2, especially at higher exposure times.
On the other hand, all suspensions with LPO showed
remarkably high antimicrobial effectiveness. In the quan-
titative suspension test, the lactoperoxidase-thiocyanate-
hydrogen peroxide system (group B) showed its maximal
reduction (complete) of Streptococcus mutans (RF 7.49)
after a 5-min incubation time. Both reduction factors
(after 5 and 15 min) were statistically significantly differ-
ent from group A (without LPO).
The results show the large effect of the LPO enzyme on
antibacterial effectiveness of the lactoperoxidase-thiocy-
anate-hydrogen peroxide system, which can be a powerful
bactericide, not just bacteriostatic, if all components are
above their physiological levels. It is assumed that the
effect is based on not just the described shift of OSCN- to
HOSCN (pH 5.3) [38] but also a higher amount of the
more effective LPO-caused oxidation products, O2SCN-
and O3SCN- [21,23,28].
In the case of Streptococcus sanguinis, the reduction fac-
tor at 5 min (RF 4.01) was statistically significantly higher
in comparison with the reduction factor at 3 min (RF
0.78) of Group B (with LPO). However, there was no sta-
tistically significant difference between the reduction fac-
tors at 5 min in either group (A and B), despite a great
difference in their mean values. The reason was the large
standard deviation of in RF (4.01 ± 3.88).
We assume that, when the 5-min measurement was taken,
the bactericidal effect by HOSCN/OSCN- was already
occurring in some experiments but not yet in others. One
of the reasons could be the NAD(P)H-OSCN- oxidore-
ductase system, which Streptococcus mutans and Strepto-
coccus sanguinis and other bacteria have. This system can
reduce HOSCN/OSCN- to the less effective components,
SCN- and H2O2. Streptococcus sanguinis has more of this
reducing enzyme than does Streptococcus mutans. Thus,
we assume that a higher concentration of HOSCN/OSCN-
is needed to achieve a similar bactericidal effect on Strep-
tococcus sanguinis than on Streptococcus mutans [40,41],
meaning more time in the experiment. After 15 min, the
test suspension with LPO had a similar antibacterial effec-
tiveness on Streptococcus sanguinis (RF 8.12 ± 0.22) as on
Streptococcus mutans (RF 7.41 ± 0.69).
Rosin et al. [32] used more than the physiological level of
SCN--H2O2 in a toothpaste to increase the human oral
defence system. This toothpaste reduced gingivitis and
inhibited plaque. The enhancement of these effects by an
optimal combination not only of H2O2 and thiocyanate,
but also of LPO enzyme, for mouth rinses or toothpaste
formula is certainly possible and should be considered in
further clinical studies.
In our study, the LPO system was bactericidal at pH 5.3 to
Streptococcus mutans and sanguinis. However, experi-
ments by Thomas et al. [29] showed that the LPO system
was effectively bacteriostatic, but not bactericidal, at pH 7
during a 1-h incubation. This finding may mean that the
LPO system might shift from bacteriostatic to bactericidal
at a point when the Streptococcus mutans causes low pH
(<5.5), leading, for example, to demineralisation of tooth
hard substances. Thus, the system could be a reservoir,
getting its highest antibacterial activity when it is most
needed: at a point when pH falls as a result of bacterial lac-
tic acid production.
After 3 min, the reduction of Candida albicans in the test
suspension with LPO was already complete. Thus, of the
three tested microorganisms, Candida albicans was most
sensitive to the lactoperoxidase-thiocyanate-hydrogen
peroxide system, even if it was buffered by phosphate.
Majerus and Courtois [42], as well as Samant et al. [43],
could not find a sufficient antifungal effect of the SCN--
H2O2-LPO system. Lenander-Lumikari [22] found that C.
albicans is sensitive to HOSCN/OSCN-, but saliva and sal-
ivary concentrations of phosphate blocked the antifungal
effect of the peroxidase systems. However, they used all
components of this system at the physiological human
saliva level.
Thus, the lactoperoxidase-thiocyanate-hydrogen peroxide
system can be not only fungistatic [44] but also fungicidal
for Candida albicans; independently, it is phosphate-buff-
ered at salivary concentrations or higher.
C. albicans can be isolated from the mouth of most indi-
viduals, but the fungus causes oral disease such as oral
mucositis in primarily immunocompromised individuals
[45-47]. Further, Candida albicans is seen as a reservoir
for pneumonia [48] and intestinal related diseases [49].
Theraud et al. [50] showed that chlorhexidine was fungi-
cidal on pure cultures, yeast mixtures, and biofilms above
a concentration level of 0.5% (w/w). However, Pitten et
al. [51] showed that treatment with a 0.3% (w/w) chlo-
rhexidine-based product did not provide a clinical benefitPage 5 of 8
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nia. In their study, the risk of mucositis and clinical seque-
lae (e.g., C-reactive protein) seemed to be enhanced by
chlorhexidine mouth rinse, although the counts of micro-
organisms on the oral mucous membranes were signifi-
cantly reduced. They assumed that the reason was the
reduced tissue tolerance to chlorhexidine. This assump-
tion is supported by a study that showed a discrepancy
between antiseptic activity and clinical effect on radiation-
induced [52] or chemo-induced mucositis [53] by chlo-
rhexidine mouth rinse compared with placebo. In a peri-
toneal explant test for evaluating tissue tolerance,
chlorhexidine showed the highest cytotoxicity in compar-
ison to an essential oil and an amine/stannous fluoride
mouth rinse [54]. Thus, it could be interesting to increase
host innate defence systems, such as the lactoperoxidase-
thiocyanate-hydrogen peroxide system, which have no or
low effectiveness at the physiological level, by increasing
their level of concentration instead of using common anti-
septics.
Conclusion
In summary, in the quantitative suspension test, the SCN-
and H2O2 mixture above normal physiological saliva lev-
els showed little or no antimicrobial effect within 15 min.
However, by adding lactoperoxidase enzyme, the tested
mixtures became not only an effective bactericidal (Strep-
tococcus mutans and sanguinis) but also a fungicidal
(Candida albicans) agent. Thus, all three components of
the LPO-system are needed for its microbicidal effect. Sub-
sequent studies should consider loading tests with human
saliva and different concentrations of all three compo-
nents.
Methods
The study was performed based on the European norms
(EN) 1040 and EN 1275. A 9.9-ml test solution (with and
without LPO) was mixed with a 0.1-ml bacteria or fungus
suspension (overnight culture) and stored at 37°C.
After 1, 3, 5, and 15 min contact time, the test mixture was
again well mixed (vortexed), and 1 ml was transferred into
9 ml of neutralizer (polysorbate 80 30 g/L, lecithin 3 g/L,
L-histidine 1 g/L, sodium thiosulfate 5 g/L, aqua bidestil-
lata ad 1000 mL). The neutralizer was tested in a prestudy
according to the recommended neutralization test of the
German Society for Hygiene and Microbiology (DGHM).
After 5 min of neutralization time, 1.0 ml of the neutral-
ized test suspension was mixed with 9.0 ml of dilution
solution, and 0.1 ml of this final solution was spread on
tryptone soya agar (TSA, Oxoid, Germany) plates. After
42–48 h of aerobic incubation at 36°C (± 1°C), macro-
scopically visible colonies were counted on the plates. The
arithmetic means of the duplicates were calculated with
the plates of 15–300 colony-forming units (cfu) as recom-
mended by European norms. Every trial was conducted
separately seven times, and the arithmetic means with the
corresponding standard deviations were calculated.
Before each experiment was conducted, all components
were prepared as follows.
Test organisms
Preservation and culture of the test organisms (Strepto-
coccus mutans ATCC 35668, sanguinis ATCC 10556, and
Candida albicans ATCC 10231) were conducted corre-
sponding largely to EN 1040 and EN 1275 (adjusted
number of cells in the suspension: 1.5 × 108 – 5.0 × 108
cfu/ml for bacteria and 1.5 × 107 – 5.0 × 107cfu/ml for
fungi).
Solutions of test mixtures
Buffer adjusted to pH 5.3: 7 parts 0.2 M KH2PO4, 1 part
0.2 M K2HPO4; SCN- solution (2% w/v; 0.34 M): 2.8 g
NaSCN/100 ml freshly glass-distilled water; H2O2 solu-
tion (0.4% w/v; 0.12 M): 1.12 g carbamide peroxide
(CH4N2O.H2O2)/100 ml glass-distilled water (prepared
immediately before the trial); buffer-LPO solution: 5.0 mg
LPO (210 U/mg, Fluka) dissolved in 0.250 ml glycerine
and 0.250 ml phosphate buffer saline solution, adding 5
ml of the buffer to pH 5.3.
Test mixtures and control
Group A contained 5.0 ml buffer solution (pH 5.3), 2.5
ml SCN- solution (2.0% w/v; 0.34 M), and 2.5 ml H2O2
solution (0.4% w/v; 0.12 M); Group B contained 4.0 ml
buffer solution (pH 5.3), 2.5 ml SCN- solution (2.0% w/
v; 0.34 M), 2.5 ml H2O2 solution (0.4% w/v; 0.12 M), and
1 ml buffered-LPO solution. Thus, the LPO concentration
in this solution was 83 mg/ml.
The control group contained 5.0 ml buffer solution (pH
5.3) and 5.0 ml water with standardized hardness. All pre-
pared solutions were stored at 37°C until use.
In the same manner, all single components (H2O2, SCN-,
LPO) or their combinations (LPO+SCN-, LPO+H2O2)
were tested for their antimicrobial effects in accompany-
ing suspension tests.
Statistical analysis
The microbial counts were expressed as their decimal log-
arithms. The reduction factor (RF) was calculated as fol-
lows:
where cfu c = number of cfu per ml control medium
(water with standardized hardness), and cfu tA/B = number
of cfu per ml test group A or B.
lg RF l g cfu c l g cfu t A/B= -( ) ( ),Page 6 of 8
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BMC Microbiology 2009, 9:134 http://www.biomedcentral.com/1471-2180/9/134The comparisons at the time points between groups A and
B (without and with LPO, respectively) were performed
with the Mann-Whitney U test and within groups with the
Wilcoxon test. All statistical analyses were carried out with
SPSS 11.5.
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